BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

September 08, 2026

Performance

52-Week Range 81.0% below 52-week high

2.820

2.8152W Low 14.8752W High

1 Week 16.3% below 1-week high

2.811W Low 3.371W High

BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT) traded between $2.81 and $14.87 over the past 52 weeks and last traded at $2.82, 81.0% below its 52-week high. Over the past week it ranged between $2.81 and $3.37.

Past 12 Months

-13.5%

-40.9%

-66.5%

-69.5%

-77.1%

-74.9%

1W -$0.44

1M -$1.95

3M -$5.60

6M -$6.44

YTD -$9.47

1Y -$8.43

BBOT was -74.9% over the past year, -69.5% over six months, -77.1% year to date, -13.5% in the last week.

12 Months vs Market

BBOT

-74.9%

DIA

+11.2%

SPY

+13.7%

QQQ

+16.1%

IWM

+9.0%

Over the past 12 months BBOT returned -74.9% versus DIA (Dow) +11.2%, SPY (S&P 500) +13.7%, QQQ (Nasdaq 100) +16.1% and IWM (Russell 2000) +9.0%.

Volume & Liquidity 0.00× 3-mo avg

Today 315 3-mo avg 472.4K

427.0K

579.2K

472.4K

465.2K

YTD

405.8K

355.5K

BBOT most recently traded 315 shares against a 3-month average daily volume of 472.4K.

More News

BBOT to Participate in Upcoming Investor Healthcare Conferences

September 01, 2026

Which stocks are gapping on Wednesday? ↗

July 08, 2026

Via Chartmill

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗

May 17, 2026

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗

May 17, 2026

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗

May 15, 2026

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗

May 15, 2026

Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗

May 15, 2026

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 12, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 12, 2026

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

April 22, 2026

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

April 22, 2026

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

April 21, 2026

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

What's going on in today's after hours session ↗

April 20, 2026

Via Chartmill

April 20, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 18, 2026

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

March 06, 2026

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

March 05, 2026